quadrivalent influenza virus split vaccine
/ Chongqing Zhifei
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
January 02, 2024
Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine
(clinicaltrials.gov)
- P3 | N=2550 | Completed | Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Influenza • Respiratory Diseases
May 15, 2023
Quadrivalent Influenza Virus Split Vaccine
(clinicaltrials.gov)
- P3 | N=2550 | Active, not recruiting | Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases
March 07, 2023
Quadrivalent Influenza Virus Split Vaccine
(clinicaltrials.gov)
- P3 | N=2550 | Recruiting | Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Influenza • Respiratory Diseases
1 to 3
Of
3
Go to page
1